Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propylthiouracil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7161078 | 0.88 | GPR84 (0.50) | BACE1CYP1A2MAPTALDH1A1NPSR1 | |
| SCHEMBL6927978 | 0.86 | GPR84 (0.51) | BACE1CYP1A2KMT2A | |
| SCHEMBL6931321 | 0.86 | GPR84 (0.51) | BACE1CYP1A2KMT2A | |
| SCHEMBL6998274 | 0.85 | LMNA (0.47) | BACE1CYP1A2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4306387 | 0.79 | BACE1 (0.66) | BACE1CYP1A2MAPTALDH1A1NPSR1 | |
| SCHEMBL4809195 | 0.78 | BACE1 (1.00) | BACE1CYP1A2MAPTALDH1A1NPSR1 | |
| SCHEMBL2786194 | 0.75 | CYP1A2 (0.73) | BACE1CYP1A2MAPTALDH1A1NPSR1 | |
| SCHEMBL9414223 | 0.75 | BACE1 (0.60) | BACE1CYP1A2MAPTALDH1A1NPSR1 | |
| SCHEMBL26063171 | 0.71 | CYP1A2 (0.77) | CYP1A2MAPTALDH1A1NPSR1HSD17B10 | |
| SCHEMBL26064133 | 0.71 | CYP1A2 (0.68) | BACE1CYP1A2MAPTALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064785-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| US-12171749-B2 | Thioureylene liquid compositions | NORBROOK LABORATORIES LIMITED (GB) | 2024-12-24 | — | — | US | disclosed |
| US-20230404978-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2023-12-21 | — | — | US | disclosed |
| US-11738005-B2 | Thioureylene liquid compositions | NORBROOK LABORATORIES LIMITED (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-3160441-B1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LAB LTD (GB) | 2022-01-12 | — | — | EP | disclosed |
| US-20210361623-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2021-11-25 | — | — | US | disclosed |
| US-11123327-B2 | Thioureylene liquid compositions | NORBROOK LABORATORIES LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| EP-3441063-B1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LAB LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| US-20200405690-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2020-12-31 | — | — | US | disclosed |
| EP-3441063-A1 | THIOUREYLENE LIQUID COMPOSITIONS | Norbrook Laboratories Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-20180318262-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LABORATORIES LIMITED (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20170135987-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2017-05-18 | — | — | US | disclosed |
| EP-3160441-A1 | THIOUREYLENE LIQUID COMPOSITIONS | Norbrook Laboratories Limited (GB) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015198033-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LABORATORIES LIMITED (GB) | 2015-12-30 | — | — | WO | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361623-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | BACE1 4469/4885CYP1A2 2044/4885MAPT 1564/4885 |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | BACE1 1853/4885CYP1A2 2055/4885MAPT 898/4885 |
| US-20230404978-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | BACE1 4469/4885CYP1A2 2044/4885MAPT 1564/4885 |
| US-20200405690-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | BACE1 4469/4885CYP1A2 2044/4885MAPT 1564/4885 |
| US-20250064785-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | BACE1 4469/4885CYP1A2 2044/4885MAPT 1564/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | BACE1 1853/4885CYP1A2 2055/4885MAPT 898/4885 |
| US-20170135987-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | BACE1 4469/4885CYP1A2 2044/4885MAPT 1564/4885 |
| US-11738005-B2 | Thioureylene liquid compositions | TPO, TSHR, TRHDE | BACE1 4469/4885CYP1A2 2044/4885MAPT 1564/4885 |
| US-11123327-B2 | Thioureylene liquid compositions | TPO, TSHR, TRHDE | BACE1 4469/4885CYP1A2 2044/4885MAPT 1564/4885 |
| US-12171749-B2 | Thioureylene liquid compositions | TPO, TSHR, TRHDE | BACE1 4469/4885CYP1A2 2044/4885MAPT 1564/4885 |
| US-20180318262-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | BACE1 4469/4885CYP1A2 2044/4885MAPT 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.